Dexrazoxane (dexrazoxane for injection) NDC 72266-235

NDC codes

FDA NDC Directory

Product NDC (as listed)72266-235Labeler and product segments. Claims need a package NDC.

Product NDC at billing width72266-0235Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
72266-235-01	72266023501	1 VIAL in 1 CARTON (72266-235-01) / 25 mL in 1 VIALMarketed from Nov 1, 2021

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Dexrazoxane
Generic name (nonproprietary): dexrazoxane for injection
Active ingredients: Dexrazoxane hydrochloride — 250 mg/25mL
Dosage form: Injection, Powder, Lyophilized, For solution
Route: Intravenous
Labeler: Fosun Pharma USA Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 207321
Marketing start: Nov 1, 2021
Listing expires: Dec 31, 2026
Identifiers: Product ID 72266-235_39134f54-58a4-ca41-e063-6394a90ac300SPL ID 39134f54-58a4-ca41-e063-6394a90ac300SPL set ID c1d98fbe-5fd9-4518-b1a5-fac92e32928fRxCUI 1736585, 1736590UNII 5346058Q7SUPC 0372266101013, 0372266235015
Pharmacologic class: Cytoprotective Agent

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N472266023501 followed by a unit qualifier and the quantity

Package 72266-0235-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jun 17, 2025.

Indications (excerpt from the label)

Dexrazoxane for injection is indicated for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m 2 and who will continue to receive doxorubicin therapy to maintain tumor control. Do not use with the initiation of doxorubicin therapy [see Warnings and Precautions ( 5.2 )] . Dexrazoxane for injection is a cytoprotective agent indicated for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m 2 and who will continu…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 207321

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 207321
Product	Strength	Form · route	Labeler	Product NDC
Dexrazoxanedexrazoxane for injection	Dexrazoxane hydrochloride 500 mg/50mL	Injection, Powder, Lyophilized, For solutionIntravenous	Fosun Pharma USA Inc.	72266-101
Dexrazoxanedexrazoxane for injection	Dexrazoxane hydrochloride 500 mg/50mL	Injection, Powder, Lyophilized, For solutionIntravenous	Gland Pharma Limited	68083-195
Dexrazoxanedexrazoxane for injection	Dexrazoxane hydrochloride 250 mg/25mL	Injection, Powder, Lyophilized, For solutionIntravenous	Gland Pharma Limited	68083-388
Dexrazoxanedexrazoxane for injection	Dexrazoxane hydrochloride 500 mg/50mL	Injection, Powder, Lyophilized, For solutionIntravenous	Almaject, Inc.	72611-716
Dexrazoxanedexrazoxane for injection	Dexrazoxane hydrochloride 500 mg/50mL	Injection, Powder, Lyophilized, For solutionIntravenous	Almaject, Inc.	72611-716